The MDA is a nonprofit health organization dedicated to educating and empowering patients with AMD.
Editor’s Note: Welcome to “Let's Chat,” a blog series featuring contributions from members of the ophthalmic community. These blogs are an opportunity for ophthalmic bloggers to engage with readers with about a topic that is top of mind, whether it is practice management, experiences with patients, the industry, medicine in general, or healthcare reform. The series continues with this blog by Joshua Mali, MD. The views expressed in these blogs are those of their respective contributors and do not represent the views of Ophthalmology Times or MultiMedia Healthcare, LLC.
I am happy to announce a new initiative by the Macular Degeneration Association (MDA): AMD Centers of Excellence (COE). This program shares best-practice methods in disease evaluations and treatments. This age-related macular degeneration (AMD) COE will help patients locate outstanding treatment facilities in their area.
Founded in 2007, the MDA is a nonprofit health organization dedicated to educating and empowering patients with AMD. The MDA funds research, publishes scientific findings, and provides funding for AMD awareness programs. The association is also involved in advocating for scientific research and the rights of people with AMD.
As a keynote speaker for the organization, I have had the joy of participating in patient education programs. These programs allow AMD patients and their family/caretakers to take control of their disease through education.
Here are some of the highlighted criteria for an AMD COE with the MDA accreditation:
- Facility should have all applicable diagnostic testing equipment available at the physical site such as a spectral-domain or swept-source OCT device, fundus photography, autofluorescence, fluorescein angiogram, and diagnostic testing equipment.
- Testing equipment must be calibrated and maintained per equipment instructions and in compliance with applicable manufacturer’s suggested maintenance and calibration standards.
- At a minimum, at least 30% of the practice should be AMD patients
- Participate in a multicenter study investigating a new treatment for AMD
- Lecture on AMD
- Author a paper or publication on AMD
In anticipation of retina specialists receiving a formal invitation to participate in this valuable patient resource, go to the MDA website, www.macularhope.org, for more updates and information.
Joshua Mali, MD
Dr. Mali is the founder & CEO of Mali Enterprises. His relevant financial disclosures include the following: speaker, consultant, and medical director of the Macular Degeneration Association (MDA).